Glenmark gets tentative nod from USFDA for generic type-2 diabetes tablets
Drug
firm Glenmark Pharmaceuticals on Monday said it has
received tentative approval from the US health regulator for generic
Dapagliflozin tablets used for treatment of type-2 diabetes.
The
product is a generic version of AstraZeneca AB's Farxiga tablets.
"Glenmark
Pharmaceuticals Inc USA has been granted tentative approval by the United
States Food and Drug Administration (USFDA) for Dapagliflozin tablets, 5 mg and
10 mg," Glenmark said in a filing to BSE.
Citing
IQVIA sales data for the 12 month period ending January 2020, the company said
Farxiga tablets, brand and all available therapeutic equivalents in strengths
of 5 mg and 10 mg, achieved annual sales of approximately $1.8 billion. Read More
Comments
Post a Comment